Paper Details

  1. Home
  2. Paper Details

The immunomodulatory effects of roflumilast on tachyzoite-bradyzoite transition in a murine model of Toxoplasma gondii.

Author: AboukamarWafaa A, ElmasryAhlam, ElmehankarManar S, HanyHeba

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

Roflumilast, a PDE-4 inhibitor, shows potential for controlling toxoplasmosis by halting tachyzoite-bradyzoite transition. The early treated group at 10 mg/kg exhibited a significant reduction in cyst count, size, and IL-12 levels, suggesting its promise for further investigation.
Paper Details　
Original Abstract of the Article :
Roflumilast, a phosphodiesterase 4-inhibitor (PDE-4), shows immunomodulatory and anti-inflammatory properties. It modulates cAMP and TNF-α levels that play a role in the differentiation of Toxoplasma gondii (T. gondii) tachyzoite to bradyzoite stage. Thus, the potential effect of Roflumilast on the ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.intimp.2022.109348

データ提供：米国国立医学図書館（NLM）

Roflumilast: A Potential Treatment for Toxoplasmosis?

Toxoplasmosis is a parasitic infection caused by the protozoan Toxoplasma gondii. This study, published in Parasitology Research, explored the immunomodulatory effects of roflumilast, a phosphodiesterase 4 inhibitor (PDE-4), on the tachyzoite-bradyzoite transition in a murine model of Toxoplasma gondii infection.

Roflumilast Shows Potential for Controlling Infection

The study found that early treatment with roflumilast at a dose of 10 mg/kg significantly reduced the number and size of T. gondii cysts in the brains of infected mice. This suggests that roflumilast may have potential as a therapeutic agent for controlling Toxoplasma gondii infection.

Understanding the Role of Immunomodulation in Infection

This study contributes to our understanding of the immunomodulatory effects of roflumilast in the context of Toxoplasma gondii infection. It highlights the potential of targeting specific pathways involved in the parasite's lifecycle as a strategy for developing effective treatments.

Dr.Camel's Conclusion

Toxoplasmosis, like a desert scorpion lurking in the sand, can be a formidable foe. This study explores the potential of roflumilast as a weapon against this parasite. The findings suggest that roflumilast might offer a new approach to managing toxoplasmosis, providing a promising avenue for future research and development of effective treatments.
Date :
  1. Date Completed 2022-12-02
  2. Date Revised 2022-12-02
Further Info :

Pubmed ID

36306559

DOI: Digital Object Identifier

10.1016/j.intimp.2022.109348

Related Literature

Article Analysis
・Effects of roflumilast
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.